BNP Paribas Arbitrage SNC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

BNP Paribas Arbitrage SNC grew its stake in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 88.4% during the 3rd quarter, Holdings Channel reports. The fund owned 284,129 shares of the medical equipment provider’s stock after acquiring an additional 133,290 shares during the period. BNP Paribas Arbitrage SNC’s holdings in Hologic were worth $18,332,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bradley Mark J. increased its stake in Hologic by 5.8% during the third quarter. Bradley Mark J. now owns 41,310 shares of the medical equipment provider’s stock worth $2,666,000 after acquiring an additional 2,265 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of Hologic by 9.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 31,522 shares of the medical equipment provider’s stock worth $2,034,000 after purchasing an additional 2,614 shares during the last quarter. State Street Corp lifted its holdings in shares of Hologic by 0.6% in the 3rd quarter. State Street Corp now owns 11,550,359 shares of the medical equipment provider’s stock worth $745,229,000 after purchasing an additional 73,451 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in Hologic by 0.4% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 88,660 shares of the medical equipment provider’s stock valued at $5,720,000 after acquiring an additional 354 shares during the period. Finally, Summit Global Investments increased its position in Hologic by 4.3% in the 3rd quarter. Summit Global Investments now owns 105,011 shares of the medical equipment provider’s stock valued at $6,775,000 after acquiring an additional 4,375 shares during the period. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of the company’s stock in a transaction dated Tuesday, February 7th. The shares were sold at an average price of $85.28, for a total value of $778,435.84. Following the transaction, the insider now directly owns 14,298 shares in the company, valued at approximately $1,219,333.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HOLX shares. Royal Bank of Canada started coverage on Hologic in a research report on Tuesday, December 6th. They set a “sector perform” rating and a $75.00 price target on the stock. Cowen lifted their target price on shares of Hologic from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, February 2nd. Citigroup lifted their target price on shares of Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Thursday, February 2nd. Wells Fargo & Company lifted their target price on shares of Hologic from $75.00 to $80.00 and gave the company an “equal weight” rating in a report on Tuesday, January 10th. Finally, Mizuho lifted their target price on shares of Hologic from $77.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, January 24th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $84.08.

Hologic Stock Up 1.4 %

Shares of NASDAQ HOLX opened at $79.36 on Wednesday. The firm’s 50-day moving average price is $80.95 and its 200-day moving average price is $73.85. The company has a current ratio of 4.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $19.57 billion, a price-to-earnings ratio of 20.24, a P/E/G ratio of 1.37 and a beta of 1.01. Hologic, Inc. has a 12-month low of $59.78 and a 12-month high of $86.65.

Hologic (NASDAQ:HOLX – Get Rating) last issued its quarterly earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 EPS for the quarter, beating the consensus estimate of $0.90 by $0.17. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 22.17% and a return on equity of 25.12%. The firm’s revenue was down 27.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.17 EPS. On average, equities research analysts anticipate that Hologic, Inc. will post 3.74 EPS for the current fiscal year.

Hologic Company Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.